These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 34638038)

  • 1. The release of abuse-deterrent OxyContin and adolescent heroin use.
    DiNardi M
    Drug Alcohol Depend; 2021 Dec; 229(Pt B):109114. PubMed ID: 34638038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of the abuse-deterrent reformulation of extended-release OxyContin on prescription pain reliever misuse and heroin initiation.
    Wolff C; Dowd WN; Ali MM; McClellan C; Meinhofer A; Glos L; Mutter R; Rosenberg M; Schick A
    Addict Behav; 2020 Jun; 105():106268. PubMed ID: 32036188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin.
    Cicero TJ; Ellis MS
    JAMA Psychiatry; 2015 May; 72(5):424-30. PubMed ID: 25760692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse health effects of abuse-deterrent opioids: Evidence from the reformulation of OxyContin.
    Beheshti D
    Health Econ; 2019 Dec; 28(12):1449-1461. PubMed ID: 31715653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone.
    Severtson SG; Ellis MS; Kurtz SP; Rosenblum A; Cicero TJ; Parrino MW; Gilbert MK; Buttram ME; Dasgupta N; BucherBartelson B; Green JL; Dart RC
    Drug Alcohol Depend; 2016 Nov; 168():219-229. PubMed ID: 27716575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of abuse-deterrent OxyContin on prescription opioid utilization.
    Hwang CS; Chang HY; Alexander GC
    Pharmacoepidemiol Drug Saf; 2015 Feb; 24(2):197-204. PubMed ID: 25393216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics.
    Coplan PM; Kale H; Sandstrom L; Landau C; Chilcoat HD
    Pharmacoepidemiol Drug Saf; 2013 Dec; 22(12):1274-82. PubMed ID: 24123484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of nonmedical use of OxyContin and other prescription opioid pain relievers before and after the introduction of OxyContin with abuse deterrent properties.
    Cheng HG; Coplan PM
    Postgrad Med; 2018 Aug; 130(6):568-574. PubMed ID: 29978755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Transitioning Epidemic: How The Opioid Crisis Is Driving The Rise In Hepatitis C.
    Powell D; Alpert A; Pacula RL
    Health Aff (Millwood); 2019 Feb; 38(2):287-294. PubMed ID: 30715966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in the Nonmedical Use of OxyContin, United States, 2006 to 2013.
    Jones CM; Muhuri PK; Lurie PG
    Clin J Pain; 2017 May; 33(5):452-461. PubMed ID: 27513641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring of internet forums to evaluate reactions to the introduction of reformulated OxyContin to deter abuse.
    McNaughton EC; Coplan PM; Black RA; Weber SE; Chilcoat HD; Butler SF
    J Med Internet Res; 2014 May; 16(5):e119. PubMed ID: 24800858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reformulation of oxycodone 80 mg to prevent misuse: A cohort study assessing the impact of a supply-side intervention.
    Nolan ML; Harocopos A; Allen B; Paone D
    Int J Drug Policy; 2020 Sep; 83():102848. PubMed ID: 32645583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing the effects of decreasing prescription opioid shipments and the release of an abuse deterrent OxyContin formulation on opioid overdose fatalities in WV: an interrupted time series study.
    Lundstrom EW; Dai Z; Groth CP; Hendricks B; Winstanley EL; Abate M; Smith GS
    Subst Abuse Treat Prev Policy; 2024 Jan; 19(1):4. PubMed ID: 38178238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abuse of reformulated OxyContin: Updated findings from a sentinel surveillance sample of individuals assessed for substance use disorder.
    Cassidy TA; Thorley E; Black RA; DeVeaugh-Geiss A; Butler SF; Coplan P
    J Opioid Manag; 2017; 13(6):425-440. PubMed ID: 29308589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation.
    Sessler NE; Downing JM; Kale H; Chilcoat HD; Baumgartner TF; Coplan PM
    Pharmacoepidemiol Drug Saf; 2014 Dec; 23(12):1238-46. PubMed ID: 24916486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of an abuse-deterrent opioid formulation (OxyContin) on opioid abuse-related outcomes in the postmarketing setting.
    Coplan PM; Chilcoat HD; Butler SF; Sellers EM; Kadakia A; Harikrishnan V; Haddox JD; Dart RC
    Clin Pharmacol Ther; 2016 Sep; 100(3):275-86. PubMed ID: 27170195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating the potential impact of a reformulated version of oxycodone upon tampering, non-adherence and diversion of opioids: the National Opioid Medications Abuse Deterrence (NOMAD) study protocol.
    Degenhardt L; Larance B; Bruno R; Lintzeris N; Ali R; Farrell M
    Addiction; 2015 Feb; 110(2):226-37. PubMed ID: 25358480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased diversion by doctor-shopping for a reformulated extended release oxycodone product (OxyContin).
    Chilcoat HD; Coplan PM; Harikrishnan V; Alexander L
    Drug Alcohol Depend; 2016 Aug; 165():221-8. PubMed ID: 27372220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent trends in heroin and pharmaceutical opioid-related harms in Victoria, Australia up to 2018.
    Lam T; Kuhn L; Hayman J; Middleton M; Wilson J; Scott D; Lubman DI; Smith K; Nielsen S
    Addiction; 2020 Feb; 115(2):261-269. PubMed ID: 31465131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the effectiveness of reformulated extended-release oxycodone with abuse-deterrent properties on reducing non-oral abuse among individuals assessed for substance abuse treatment with the Addiction Severity Index-Multimedia Version (ASI-MV).
    Rodriguez RD; Dailey Govoni T; Rajagopal V; Green JL
    Curr Med Res Opin; 2023 Apr; 39(4):579-587. PubMed ID: 36762423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.